Importance of the treatment package time in surgery and postoperative radiation therapy for squamous carcinoma of the head and neck
- PMID: 11891941
- DOI: 10.1002/hed.10038
Importance of the treatment package time in surgery and postoperative radiation therapy for squamous carcinoma of the head and neck
Abstract
Background: To determine the effect of treatment time-related factors on outcome in patients treated with surgery and postoperative radiation therapy (RT) for locally advanced squamous cell carcinoma of head and neck (SCCHN) METHODS: A retrospective review was performed on 208 consecutive patients treated from 1992 to 1997 with surgery and postoperative RT (> or =55 Gy) for SCCHN. The treatment time factors considered were (1) interval from surgery to the start of RT; (2) RT duration; and (3) the total time from surgery to completion of RT (treatment package time). Treatment package time was dichotomized into short (< or =100 days) vs long (>100 days) categories. Other variables considered were clinical and pathologic staging, margin status, RT dose, and tumor site. Patients were also divided into intermediate- and high-risk groups on the basis of eligibility for RTOG 95-01. Univariate (logrank) and multivariate analyses were performed.
Results: Median follow-up for surviving patients was 24 months. Actuarial 2-year locoregional control (LRC) and survival rates were 82% and 71%, respectively. In univariate analysis, factors associated with higher locoregional failure were high-risk group (p =.011), margin status (p =.038), pathologic stage (p =.035), clinical N stage (p =.006), package time (p =.013), and RT treatment time (p =.03). Package time was also a significant predictor of survival in univariate analysis (p =.021). The other two individual time factors, tumor factors, and RT dose were not significant. Both risk status and treatment package time were significant factors in a multivariate model of LRC.
Conclusions: A total treatment package time of <100 days is associated with improved tumor control and survival. Every effort should be made to keep the time from surgery to the completion of postoperative RT to <100 days.
Copyright 2002 John Wiley & Sons, Inc.
Similar articles
-
Randomized trial addressing risk features and time factors of surgery plus radiotherapy in advanced head-and-neck cancer.Int J Radiat Oncol Biol Phys. 2001 Nov 1;51(3):571-8. doi: 10.1016/s0360-3016(01)01690-x. Int J Radiat Oncol Biol Phys. 2001. PMID: 11597795 Clinical Trial.
-
Final Report of a Prospective Randomized Trial to Evaluate the Dose-Response Relationship for Postoperative Radiation Therapy and Pathologic Risk Groups in Patients With Head and Neck Cancer.Int J Radiat Oncol Biol Phys. 2017 Aug 1;98(5):1002-1011. doi: 10.1016/j.ijrobp.2017.02.218. Epub 2017 Jul 10. Int J Radiat Oncol Biol Phys. 2017. PMID: 28721881 Free PMC article. Clinical Trial.
-
Predictors of response and survival after concurrent chemotherapy and radiation for locally advanced squamous cell carcinomas of the head and neck.Cancer. 2001 Feb 1;91(3):548-54. doi: 10.1002/1097-0142(20010201)91:3<548::aid-cncr1033>3.0.co;2-a. Cancer. 2001. PMID: 11169937 Clinical Trial.
-
Evolution of treatment and high-risk features in resectable locally advanced Head and Neck squamous cell carcinoma with special reference to extracapsular extension of nodal disease.J BUON. 2015 Jul-Aug;20(4):943-53. J BUON. 2015. PMID: 26416042 Review.
-
Adult soft tissue sarcomas of the head and neck treated by radiation and surgery or radiation alone: patterns of failure and prognostic factors.Int J Radiat Oncol Biol Phys. 1995 Oct 15;33(3):585-93. doi: 10.1016/0360-3016(95)00256-X. Int J Radiat Oncol Biol Phys. 1995. PMID: 7558947 Review.
Cited by
-
A prospective, single-arm, phase II clinical trial of intraoperative radiotherapy using a low-energy X-ray source for local advanced Laryngocarcinoma (ILAL): a study protocol.BMC Cancer. 2020 Aug 6;20(1):734. doi: 10.1186/s12885-020-07233-1. BMC Cancer. 2020. PMID: 32762662 Free PMC article.
-
Influence of time between surgery and postoperative radiation therapy and total treatment time in locoregional control of patients with head and neck cancer: a single center experience.Clinics (Sao Paulo). 2020;75:e1615. doi: 10.6061/clinics/2020/e1615. Epub 2020 Jul 22. Clinics (Sao Paulo). 2020. PMID: 32725072 Free PMC article.
-
The Association of Ethnicity and Oncologic Outcomes for Oral Cavity Squamous Cell Carcinoma (OSCC).Cancers (Basel). 2024 May 31;16(11):2117. doi: 10.3390/cancers16112117. Cancers (Basel). 2024. PMID: 38893235 Free PMC article.
-
A comparison of concurrent cisplatin versus cetuximab with radiotherapy in locally-advanced head and neck cancer: A bi-institutional analysis.Rep Pract Oncol Radiother. 2017 Sep-Oct;22(5):389-395. doi: 10.1016/j.rpor.2017.07.003. Epub 2017 Aug 2. Rep Pract Oncol Radiother. 2017. PMID: 28808428 Free PMC article.
-
Ensuring quality cancer care: a follow-up review of the Institute of Medicine's 10 recommendations for improving the quality of cancer care in America.Cancer. 2012 May 15;118(10):2571-82. doi: 10.1002/cncr.26536. Epub 2011 Nov 1. Cancer. 2012. PMID: 22045610 Free PMC article. Review.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical